Gina Consylman appointed main economic officer, critical genetic disease
Marcela Maus named to bluebird bio board of directors
bluebird bio and 2seventy bio to keep trader functions in September in progress of separation
Small business separation targeted for October 2021 completion
CAMBRIDGE, Mass., September 07, 2021–(Small business WIRE)–bluebird bio, Inc. (NASDAQ: BLUE) today announced crucial administration and board appointments in advance of the company’s prepared separation, qualified for mid-Oct, 2021. The business also outlined options for trader situations and participation in investor conferences main up to the separation.
“As we solution separation, we are centered on making sure that equally bluebird bio and 2seventy bio have sturdy administration teams and boards in area to carry every single corporation via its subsequent section,” said Nick Leschly, chief bluebird. “Right after an intense period of time of interior work to put together for the separation, we’re now wanting forward to partaking with key exterior stakeholders to share strategies for every single business as we in the vicinity of our specific Oct separation.”
bluebird bio administration update
“I’m thrilled to welcome Gina Consylman to the management group of bluebird bio. On the effectiveness of the prepared separation, Gina will turn out to be the chief monetary officer of bluebird bio,” explained Andrew Obenshain, president, critical genetic illness. “Her prior knowledge in a identical spin transaction and helping lead a thriving business corporation by means of periods of transform has already designed her an priceless spouse as we transfer through an crucial execution phase at bluebird.”
Gina Consylman joined bluebird in August 2021 as the CFO of the significant genetic ailment business, overseeing finance, tax, accounting, treasury, coverage and investor relations. She has about 25 years of expertise in finance, trader relations, method and company growth. Prior to becoming a member of bluebird, she served as senior vice president and CFO at Ironwood Prescribed drugs. Ahead of Ironwood, Gina served as vice president, corporate controller and principal accounting officer at Analogic Corporation, a publicly-held healthcare and protection technological innovation solutions firm, the place she oversaw the company’s world wide accounting and treasury groups. Prior to her function at Analogic, Gina served as senior director of company accounting at Biogen Inc., wherever she led the accounting teams for corporate and U.S. professional small business units.
Gina serves on the board of administrators for Assembly Biosciences, Inc. and Verastem Oncology. A Licensed General public Accountant, Gina began her job in public accounting at Ernst & Youthful LLP. She retains a B.S. in accounting from Johnson & Wales College and a M.S. in taxation from Bentley College.
bluebird bio board of administrators update
“As we strategy the launch of 2seventy bio, I’m psyched to welcome Marcela Maus to bluebird bio’s board of directors. Upon performance of the planned separation, Marcela will be part of the board of 2seventy bio,” explained Nick Leschly. “Marcela’s function as a translational medical professional-scientist in the field of immunology, notably as it relates to T-mobile immunotherapies and mobile therapies in the treatment method of cancer helps make her preferably suited to present valuable insights to the 2seventy group.”
Marcela Maus, M.D., Ph.D., is at the moment an associate professor at Harvard Professional medical College, the Paula O’Keefe chair in oncology and director of cellular immunotherapy at Mass Typical Most cancers Centre, as perfectly as an attending health practitioner in the Hematopoietic Mobile Transplant and Cell Therapy division of Oncology at Mass Typical Most cancers Heart. She is an affiliate member of the Broad Institute of Harvard and Massachusetts Institute of Technologies (MIT), and an associate member of the Ragon Institute of Mass Standard Most cancers Middle, MIT, and Harvard. Dr. Maus’ laboratory focuses on the biology of human T cell activation, costimulation, and memory, and on the application of human T cell therapies to human illness, such as ahead and reverse translation of engineered T mobile therapies in early-period medical trials.
Dr. Maus accomplished undergraduate experiments at MIT and holds graduate degrees (M.D., Ph.D.) from the College of Pennsylvania. Dr. Maus experienced in interior drugs at the College of Pennsylvania and in hematology and clinical oncology at Memorial Sloan Kettering Most cancers Center, is board-accredited in these three disciplines, and tactics professional medical oncology. She also serves on many scientific and scientific advisory boards for the biotechnology sector as very well as exterior academic health care centers.
Future investor events
Members of the administration teams of bluebird bio and 2seventy bio will participate in the next future investor conferences:
About bluebird bio, Inc.
bluebird bio is groundbreaking gene therapy with reason. From our Cambridge, Mass., headquarters, we’re establishing gene and cell therapies for serious genetic ailments and cancer, with the target that people dealing with perhaps lethal ailments with restricted remedy alternatives can reside their lives absolutely. Further than our labs, we’re performing to positively disrupt the healthcare technique to produce access, transparency and instruction so that gene remedy can become out there to all those who can reward.
bluebird bio is a human organization powered by human stories. We’re placing our care and expertise to function across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell illness, β-thalassemia and many myeloma, working with gene and mobile remedy technologies which includes gene addition, and (megaTAL-enabled) gene editing.
bluebird bio has further nests in Seattle, Clean. Durham, N.C. and Zug, Switzerland. For additional information and facts, check out bluebirdbio.com.
bluebird bio, 2seventy and 2seventy bio are logos of bluebird bio, Inc.
This release is made up of “forward-hunting statements” inside of the that means of the Personal Securities Litigation Reform Act of 1995, together with statements about the company’s economic condition, final results of operations, as well as statements pertaining to the Company’s plans and expectations for operations like the timing, leadership, framework, which include the division of belongings between bluebird bio and 2seventy bio, and the effects of a separation as very well as the company’s intention to present even further updates on the separation and the similar financing techniques for bluebird bio and 2seventy. Any ahead-searching statements are centered on management’s current expectations of long run functions and are matter to a number of dangers and uncertainties that could cause actual benefits to vary materially and adversely from individuals established forth in or implied by these types of ahead-on the lookout statements. These threats and uncertainties involve, but are not limited to, the challenges that we may possibly not entire the separation on the terms or timeline presently contemplated if at all, reach the expected benefits of a separation, and a separation could harm our enterprise, benefits of operations and economic situation the risk that the transaction might not be tax-cost-free we may perhaps be not able to make, on a well timed or value-helpful basis, the improvements needed to run as independent providers 2seventy bio’s absence of unbiased functioning historical past and the possibility that its accounting and other management techniques may not be geared up to fulfill the money reporting and other demands of functioning as an independent community business devoted economic and/or strategic funding sources may well not be offered on favorable phrases a separation or announcement thereof may well adversely affect our potential to appeal to or keep crucial personnel a separation may adversely effects the performance of advancement and commercialization attempts by us and our partners our corporations could be disrupted as a consequence of the announcement or pendency of the separation and the chance that we are not able to realize the meant advantages of resizing and reshaping our workforce. For a discussion of other dangers and uncertainties, and other vital things, any of which could cause our true results to differ from those contained in the ahead-hunting statements, see the area entitled “Hazard Variables” in our most latest Variety 10-Q, as perfectly as discussions of prospective challenges, uncertainties, and other significant factors in our subsequent filings with the Securities and Exchange Fee. All details in this press release is as of the date of the launch, and bluebird bio undertakes no obligation to update this information and facts until necessary by regulation.
Check out supply variation on businesswire.com: https://www.businesswire.com/news/residence/20210907005847/en/
Buyers & Media
Elizabeth Pingpank, 617-914-8736
Jenn Snyder, 617-448-0281